Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 4

Do eating disorders accompany metabolic syndrome in psoriasis patients? Results of a preliminary study

Authors Altunay I, Tukenmez-Demirci G, Ates, Aslı Kucukunal A, Aydın C, Karamustafalioglu, Altuntas

Published 29 August 2011 Volume 2011:4 Pages 139—143

DOI https://doi.org/10.2147/CCID.S24165

Review by Single anonymous peer review

Peer reviewer comments 2

Download Article [PDF] 

Ilknur Altunay1, Gulsen Tukenmez Demirci1, Bilge Ates1, Asli Kucukunal1, Cigdem Aydin2, Oguz Karamustafalioglu3, Yuksel Altuntas4
1Dermatology Department, Sisli Etfal Training and Research Hospital, Istanbul, Turkey; 2Psychology Department, Istanbul University, Istanbul, Turkey; 3Psychiatry Department, Sisli Etfal Training and Research Hospital, Istanbul, Turkey; 4Internal Medicine Endocrinology Department, Sisli Etfal Training and Research Hospital, Istanbul, Turkey

Background: Metabolic syndrome (MBS) has been reported as a frequent comorbidity in psoriatic patients. The main pathogenesis is considered to be inflammation in this association. MBS has been investigated in eating disorders as well. While psoriasis has some psychiatric comorbidities, the link between psoriasis, MBS, and eating disorders (EDs) is unknown.
Method: The study was designed as a cross-sectional, randomized, and controlled trial. A total of 100 patients with psoriasis were included in the study. Sociodemographic data, clinical subtype of psoriasis, Psoriasis Area and Severity Index (PASI) scores, and associated diseases were registered for each patient. The criteria for diagnosis of MBS developed by the International Diabetes Foundation (IDF) was used. These are central obesity (waist circumference ≥94 cm in men or ≥80 cm in women), plus two of the following: elevated triglycerides (≥150 mg/dL), reduced high-desity lipoprotein cholesterol (>40 mg/dL for men; >50 mg/dL for women), elevated blood pressure (≥130 mmHg systolic or ≥85 mmHg diastolic), and elevated fasting blood glucose (≥100 mg/dL). Additionally, the Eating Attitude Test (EAT), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI), and psychiatric interview were performed for all patients.
Results: There were 45 female and 55 male patients, aged between 18 and 85 years old (median 41.12 ± 16.01). MBS was present in 31% of the patients with psoriasis. There was no correlation between the severity of psoriasis and MBS. EAT scores were ≥30 in 7/100 patients. Four out of 31 patients with MBS (12.9%) had ED and 3/69 patients were without MBS (4.3%). Mean ED scores were compared statistically and the difference was significant (EAT = 17.9 ± 9.558 and 11.5 ± 7.204, P <0.001).
Conclusion: Defining risk factors leading to comorbidities is important in psoriasis. EDs seem to have an impact on the development of MBS in psoriasis. Establishment and treatment of EDs in patients with psoriasis may prevent the onset of MBS and other comorbidities due to MBS.

Keywords: obesity, abdominal obesity, binge-eating disorder, anxiety, inflammation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]